We review studies that have used diffusion imaging (DI) and magnetic resonance spectroscopy (MRS) to investigate genetic associations. A brief description of the measures obtainable with these methods and of some methodological and interpretability limitations is given. The usefulness of DI and MRS in defining intermediate phenotypes and in demonstrating the effects of common genetic variants known to increase risk for psychiatric manifestations on anatomical and metabolic phenotypes are reviewed. The main focus is on schizophrenia where the greatest amount of data has been collected. Moreover, we present an example coming from a different approach, where the genetic alteration is known (the deletion that causes Williams syndrome) and the DI phenotype can shed new light on the function of genes affected by the mutation. We conclude that, although these are still early days of this type of research and many findings remain controversial, both techniques can significantly contribute to the understanding of genetic effects in the brain and the pathophysiology of psychiatric disorders.
Keywords diffusion tensor imaging; spectroscopy; genes; psychiatric disorders
RationaleAs other reviews in this issue will expand on in more detail, there is a strong rationale for imaging genetics. The characterization of genetic mutations or common variants that impact on protein expression or function provides a natural experimental laboratory in order to understand the function of such proteins. Since imaging is the only tool that allows the description of brain phenotypes in vivo non-invasively, imaging genetics is critical to our understanding of normal and pathological anatomy and function, especially when in the case of psychiatric disorders. In this review, we will focus on diffusion imaging (DI) and magnetic resonance spectroscopy (MRS).Due to space limitations, it is impossible to review all studies contributing to this field. We will focus on schizophrenia, where we will explore studies showing whether measures derived from either methodology have intermediate phenotype status (i.e. are phenotypes present in patients and to a lesser degree in unaffected individuals at genetic risk for